Rainbow Coral Corp. RBCC Archives

MondayJun 24, 2013 12:55 pm

Rainbow Coral Corp. (RBCC) Partner Brings Space Down to Earth

One of Rainbow’s partner companies, Nano3D Biosciences (n3D), is bringing a bit of outer space down to earth, and it’s doing it for a good cause. The company has developed a way to simulate the weightlessness of outer space on a small scale, right in the lab, allowing researchers to better create and deal with 3-dimensional biological processes. With the company’s proprietary Bio-Assembler, special reagents deliver biocompatible magnetic nanoparticles to cells. Magnetic forces can then gently levitate and guide cells together as if they were weightless, to quickly induce cell-cell interactions in a true 3D environment as they would react…

MondayJun 17, 2013 3:34 pm

Rainbow Coral Corp. (RBCC) Partner Offers Cell Research Game Changer

Rainbow Coral’s partner, Nano3D Biosciences (n3D), is the creator of one of the newest 3D cell culturing technology on the market. Cells grown in 2D mono-layers simply do not replicate the complex interactions and architecture found in living organisms, which limits their use in basic life science research, toxicity testing, and drug discovery. n3D’s Bio-Assembler brings the simplicity of 2D culturing to 3D. The company’s Bio-Assembler is as simple as standard 2D techniques and faster than any other 3D cell culturing product currently available. Preparation time and cell manipulation requirements are equivalent to 2D culture. In fact, there are only…

MondayJun 10, 2013 8:41 am

Rainbow Coral Corp. (RBCC) Pursues Expansion and Explores New Funding

Rainbow Coral Corp. today told investors that it is considering new funding opportunities with promise in order to expand in the $232 billion personalized medicine market. The company is pushing forward with its aggressive expansion strategy for this year and is already poised for rapid growth. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before, and is currently in negotiations to partner with an emerging innovator in the…

WednesdayJun 05, 2013 10:18 am

Rainbow BioSciences (RBCC) Continues Potential Partner Talks with Transdermal Patch Company

Rainbow Coral Corp., via wholly owned subsidiary Rainbow BioSciences, LLC, markets and develops new medical and research technology innovations through partnerships with biotech developers. Rainbow BioSciences is currently looking to partake in the $142 billion U.S. drug delivery market as it continues partnering talks with a transdermal patch company. The transdermal delivery market is expected to increase up to $31.5 billion by 2015, and industry experts forecast the growth to continue as its applications extend to include many treatments, including nicotine addiction and Parkinson’s disease. “Personalized medicine is the future,” RBCC CEO Patrick Brownstated in the press release. “This is…

ThursdayMay 30, 2013 8:50 am

Rainbow Coral Corp. (RBCC) to Fuel Patient Demand for Personalized Medicine and Better Healthcare

Today before the opening bell, Rainbow Coral Corp. announced that it is making plans to empower patients to demand better care through both innovation and education as the company sets its sights on the fast-growing, $232 billion personalized medicine market. By delivering new technologies in the sectors of the personalized medicine field expected to see the most growth, Rainbow Coral hopes to arm patients with more effective and efficient treatment options than ever before. But, according to today’s press release, bringing new ideas and products to the marketplace is only one piece of the company’s expansion strategy. “Our ultimate goal…

TuesdayMay 28, 2013 3:34 pm

Rainbow Coral Corp. (RBCC) Forging Ahead in Biotech Breakthroughs through Intelligent Partnerships

Rainbow Coral is carving off an ever larger slice of the biosciences pie with each passing day via shrewd partnering with key product and medical technology innovators, as well as via their wholly-owned biotech subsidiary, Rainbow BioSciences, LLC, as the biotech sector alone climbs steadily upwards of some $89.8B in revenues for 2012 (Ernst & Young, Biotech Industry Report 2013). A leading example of this growth strategy by RBCC occurred in late March this year, as the company moved to form a strategic JV with the developer of an incredible sustained release drug delivery technology for biologics and other sensitive…

TuesdayMay 21, 2013 9:04 am

Rainbow Coral Corp. (RBCC) Takes Initial Steps to Acquire Tech Innovators in $142 Billion Drug Delivery Market

Today before the opening bell, Rainbow Coral announced that it has opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. This move is part of the company’s drive to carve out a share of the $142 billion U.S. drug delivery market. Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson's disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes as well as offers major advantages such as improved bioavailability, more uniform plasma levels, longer duration of action,…

MondayMay 13, 2013 9:43 am

Rainbow Coral Corp. (RBCC) Partner Nano3D Inks Distribution Deal to Send Breakthrough Cellular Technology to Market

Rainbow Coral, via wholly owned subsidiary Rainbow BioSciences LLC, seeks out new partnerships with biotechnology developers to deliver new medical technologies and innovations to market. The company today reported that one such partner, Nano3D Biosciences (n3D), is positioned to commercialize its BioAssembler product line in the U.S. marketplace through a distribution agreement with St. Louis-based scientific products distributor, MIDSCI. The BioAssembler is a breakthrough technology that allows researchers to culture cells in three dimensions, creating lifelike tissues similar to those found naturally within the body. Per the agreement, MIDSCI will market and sell BioAssembler technology to life sciences researchers in…

MondayMay 06, 2013 8:41 am

Rainbow Coral Corp. (RBCC) Partner Touted by World’s Premiere Science Journal

Nature, the world’s premiere science journal, seems to finally understand what Rainbow Coral Corp. has known for some time: The cell-growth technology pioneered by RBCC partner n3D Biosciences has the potential to completely revolutionize cellular research. n3D’s magnetic levitation technology was the subject of a feature article in the journal’s April issue titled “A Better Brew.” The system allows researchers at university laboratories and pharmaceutical companies to grow three-dimensional, lifelike microtissues similar enough to those found within the body to be used in in vivo drug-testing models. RBCC signed a joint venture agreement to help market and develop the technology…

TuesdayApr 30, 2013 8:55 am

Rainbow Coral Corp. (RBCC) Prepares for Revolution in Pharmaceutical and Insurance Industries

The rapid growth of personalized genomic medicine is poised to radically change not only the way that pharmaceutical companies develop drugs, but the way insurance companies administer healthcare plans. Acknowledging the increasing momentum, Rainbow Coral today told investors that it is forging ahead with plans for new partnerships in both genetic testing and companion diagnostics. PricewaterhouseCoopers predicts that the personalized medicine sector could grow to as much as $452 billion by 2015. One of the driving forces behind this expansion is the inefficient way in which drugs are currently produced. Because insurance companies try to avoid paying for drugs that…

Site Search

Company Search

Tag: Rainbow Coral Corp. RBCC